C.R. Bard (BCR) acquires Lutonix - a privately-held medical device developer currently...

|About: C. R. Bard, Inc. (BCR)|By:, SA News Editor

C.R. Bard (BCR) acquires Lutonix - a privately-held medical device developer currently conducting an FDA-approved investigational device exemption trial using drug-coated balloons for the treatment of peripheral arterial disease - for $225M, plus an additional $100M upon PMA approval of the device.